acute myeloid leukemia

Research in Review
Immunotherapy Diminishes Regulatory T-Cells, Improves Outcomes in AML
07/20/2017
JCP Editors
Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...
Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...
...
07/20/2017
Journal of Clinical Pathways
Research in Review
Altered B-Cell Composition May Impact Immunotherapy Effectiveness in AML
07/13/2017
JCP Editors
Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...
Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...
...
07/13/2017
Journal of Clinical Pathways
Research in Review
High-Dose Chemo Yields Similar Survival Outcomes in Patients With AML
06/22/2017
JCP Editors
Standard induction chemotherapy is noninferior to high-dose chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML), according to new research published in the Journal of Clinical Oncology...
Standard induction chemotherapy is noninferior to high-dose chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML), according to new research published in the Journal of Clinical Oncology...
...
06/22/2017
Journal of Clinical Pathways
Research in Review
B-Cell Malignancy Provides Economic Burden to US Commercial Payers
05/30/2017
JCP Editors
The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017;...
The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017;...
The...
05/30/2017
Journal of Clinical Pathways
Research in Review
Leukemia Survival Outcomes Differ Between Sites of Care
04/11/2017
JCP Editors
Sites of care may help explain survival differences between children and adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), according to research published...
Sites of care may help explain survival differences between children and adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), according to research published...
Sites...
04/11/2017
Journal of Clinical Pathways
Research in Review
Adding Androgens to Maintenance Therapy Improves Survival in Older Patients With AML
03/01/2017
JCP Editors
Maintenance therapy with androgens significantly improves survival in older patients with acute myeloid leukemia (AML) without increasing toxicity, according to research published in the Journal of Clinical Oncology...
Maintenance therapy with androgens significantly improves survival in older patients with acute myeloid leukemia (AML) without increasing toxicity, according to research published in the Journal of Clinical Oncology...
...
03/01/2017
Journal of Clinical Pathways
Research in Review
Induction Therapy With Clofarabine Shows No Survival Benefit for AML
01/16/2017
JCP Editors
Adding clofarabine to standard induction therapy shows no effect on survival for patients with newly diagnosed acute myeloid leukemia (AML), according to a study published in Blood. Standard induction treatment with...
Adding clofarabine to standard induction therapy shows no effect on survival for patients with newly diagnosed acute myeloid leukemia (AML), according to a study published in Blood. Standard induction treatment with...
Adding...
01/16/2017
Journal of Clinical Pathways
Research in Review
Novel Biomarker Helps Detect Blood Cancer Responders to Chemotherapy
01/13/2017
JCP Editors
Expression of a cellular enzyme could predict the response of patients with acute myeloid leukemia (AML) to chemotherapy, according to new research. ----- Related Content Personalized Genomic Framework Predicts...
Expression of a cellular enzyme could predict the response of patients with acute myeloid leukemia (AML) to chemotherapy, according to new research. ----- Related Content Personalized Genomic Framework Predicts...
...
01/13/2017
Journal of Clinical Pathways
Research in Review
Leukemia Cancer Cells With TP53 Mutations Respond to Mild Chemotherapy
11/28/2016
JCP Editors
Patients with acute myeloid leukemia (AML) whose cells carry TP53 mutations may survive longer if they are treated with decitabine, according to a recent study in The New England Journal of...
Patients with acute myeloid leukemia (AML) whose cells carry TP53 mutations may survive longer if they are treated with decitabine, according to a recent study in The New England Journal of...
...
11/28/2016
Journal of Clinical Pathways
Research in Review
Personalized Genomic Framework Predicts Treatment Outcomes in AML
12/10/2015
JCP Editors
Researchers have developed a novel prognostic framework using genomic sequencing data to assess risk in patients with acute myeloid leukemia (AML). Their work was presented at the American Society of Hematology (ASH)...
Researchers have developed a novel prognostic framework using genomic sequencing data to assess risk in patients with acute myeloid leukemia (AML). Their work was presented at the American Society of Hematology (ASH)...
...
12/10/2015
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use